MX362819B - Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia. - Google Patents

Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.

Info

Publication number
MX362819B
MX362819B MX2015009154A MX2015009154A MX362819B MX 362819 B MX362819 B MX 362819B MX 2015009154 A MX2015009154 A MX 2015009154A MX 2015009154 A MX2015009154 A MX 2015009154A MX 362819 B MX362819 B MX 362819B
Authority
MX
Mexico
Prior art keywords
narcolepsy
treatment
receptor agonists
alpha
nicotinic receptor
Prior art date
Application number
MX2015009154A
Other languages
English (en)
Other versions
MX2015009154A (es
Inventor
Baltazar Gomez-Mancilla
Dominik Feuerbach
Markus Fendt
Cristina Lopez-Lopez
Kevin Hall Mcallister
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015009154A publication Critical patent/MX2015009154A/es
Publication of MX362819B publication Critical patent/MX362819B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere al uso de ciertos agonistas del receptor nicotínico de acetilcolina alfa 7 para uso en el tratamiento, mejora, prevención o retraso del avance de la narcolepsia, la somnolencia excesiva durante el día, la perturbación del sueño nocturno y/o la cataplexia.
MX2015009154A 2013-01-15 2013-01-15 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia. MX362819B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/050368 WO2014111751A1 (en) 2013-01-15 2013-01-15 Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy

Publications (2)

Publication Number Publication Date
MX2015009154A MX2015009154A (es) 2016-03-04
MX362819B true MX362819B (es) 2019-02-18

Family

ID=47747729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009154A MX362819B (es) 2013-01-15 2013-01-15 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.

Country Status (9)

Country Link
EP (1) EP2945626B1 (es)
JP (1) JP6137336B2 (es)
KR (1) KR101879921B1 (es)
CN (1) CN105263492B (es)
BR (1) BR112015016994A8 (es)
CA (1) CA2898043C (es)
ES (1) ES2701083T3 (es)
MX (1) MX362819B (es)
WO (1) WO2014111751A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102636383B1 (ko) 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
JP2022521467A (ja) 2019-02-05 2022-04-08 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
US20050245567A1 (en) * 2002-08-14 2005-11-03 Dan Peters Novel quinuclidine derivatives and their use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
WO2005044267A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
EP1677788A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes iii
CA2549967A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006106523A2 (en) 2005-04-08 2006-10-12 Xtellus Inc. Multi-channel chromatic dispersion compensator
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
CA2627630A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
EP2018380B1 (en) 2006-05-19 2011-10-19 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
MX2011003429A (es) 2008-10-13 2011-05-02 Hoffmann La Roche Metodo libre de diazonio para fabricar un compuesto intermedio de indazol en la sintesis de las amidas del acido 5-(trifluorometoxi)-1h-3-indazolcarboxilico biciclico.
WO2010056622A1 (en) 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
TW201031664A (en) * 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2456438A2 (en) * 2009-07-23 2012-05-30 Novartis AG Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives

Also Published As

Publication number Publication date
WO2014111751A1 (en) 2014-07-24
KR101879921B1 (ko) 2018-07-18
CA2898043C (en) 2019-08-06
KR20150104632A (ko) 2015-09-15
MX2015009154A (es) 2016-03-04
BR112015016994A8 (pt) 2018-01-23
EP2945626A1 (en) 2015-11-25
CN105263492B (zh) 2018-04-10
CN105263492A (zh) 2016-01-20
EP2945626B1 (en) 2018-09-12
CA2898043A1 (en) 2014-07-24
JP6137336B2 (ja) 2017-05-31
ES2701083T3 (es) 2019-02-20
JP2016504407A (ja) 2016-02-12
BR112015016994A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
EP3630072A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
SG10201913054TA (en) Novel lactobacillus having various functions, and use thereof
IL283432A (en) Preparations, methods and systems for the treatment of skin disorders
EP3068289A4 (en) Prevention and treatment of bed exits, falls, and other conditions
ZA201903934B (en) Novel tnfr agonists and uses thereof
PH12015502788A1 (en) Antibody formulations and methods
EP2967978A4 (en) DEVICES, SYSTEMS AND METHOD FOR COOLING THE SKIN
RS64056B1 (sr) Kateter i sistem za krioablaciju
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
HK1250469A1 (zh) 內窺鏡系統、裝置和方法
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
ZA201705254B (en) Block copolymers and the use thereof for improving the cold properties of fuels or combustibles
PL3274388T3 (pl) Urządzenia z akustyczną i termiczną izolacją na bazie lepkosprężystego poliuretanu
AU363883S (en) Tracking device
HK1249851A1 (zh) 使用聚維酮碘的普通感冒的治療和預防
HUE046924T2 (hu) Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
ZA201705222B (en) Block copolymers and the use thereof for improving the cold properties of fuels or combustibles
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
IL251880A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX2015009154A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
EP3228677A4 (en) Friction resistance reducing agent and fire-extinguishing agent
MX2018004091A (es) Antagonistas de il-17c para el tratamiento y/o prevencion de dermatitis atopica.
HK1209367A1 (en) Use of clostridium nexile in the treatment or prevention of rheumatoid arthritis or related diseases

Legal Events

Date Code Title Description
FG Grant or registration